Semaglutide
Ozempic / Wegovy
Semaglutide is a GLP-1 receptor agonist and one of the most impactful metabolic medications of the decade — the molecule behind Ozempic (type 2 diabetes) and Wegovy (chronic weight management). This guide explains how semaglutide works, what the landmark STEP trials actually showed, how it's dosed and titrated, its side-effect profile, and how it compares to tirzepatide and retatrutide. Semaglutide is a prescription medication — this is educational information, not medical advice.
Semaglutide quick facts
| Reported research dosing | 0.25mg-2.4mg |
| Route | Subq |
| Cycle length | As Long As Needed |
| Frequency | 1-2x Weekly (Split Dose) |
| Half-life | ~7 days |
| Forms | Injectable |
| Evidence level | FDA-approved; large human trials |
The one that started the wave. Rock-solid data; titrate to manage GI side effects.
How semaglutide works
Semaglutide mimics GLP-1 (glucagon-like peptide-1), a gut hormone your body releases after eating. By activating GLP-1 receptors it does several things at once: it curbs appetite and increases fullness through effects in the brain, slows gastric emptying so you feel satisfied longer, and stimulates glucose-dependent insulin release to improve blood-sugar control. A structural modification gives it a roughly one-week half-life, enabling once-weekly injection.
What the research shows
The landmark STEP 1 trial (NEJM 2021, 1,961 adults) showed semaglutide 2.4 mg produced a mean ~14.9% body-weight reduction over 68 weeks versus 2.4% for placebo — and about 17.4% among those who reached and tolerated the maximum dose. In 2026, a higher-dose formulation, Wegovy HD (7.2 mg), was FDA-approved (March 2026); in the STEP UP trial it produced an average ~20.7% weight loss over 72 weeks in appropriate patients. Semaglutide also has cardiovascular outcome data supporting benefit in certain populations.
Approved uses & brand names
Semaglutide is sold under different brands for different approvals: Ozempic (injectable, type 2 diabetes), Wegovy (injectable, chronic weight management, up to 2.4 mg, plus the newer 7.2 mg HD), and Rybelsus (an oral tablet form for diabetes). Only a licensed prescriber can determine whether any of these is appropriate for a given person.
Dosing & titration (as prescribed / studied)
In the approved regimens, semaglutide is titrated slowly — typically starting around 0.25 mg once weekly and stepping up roughly every 4 weeks toward a maintenance dose (2.4 mg for Wegovy) as tolerated. The slow ramp matters: research shows faster titration drives more nausea, vomiting and dropouts. Any actual dosing must be set and supervised by a prescriber — the figures here summarize the studied/approved schedules for education only.
Side effects
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation and abdominal pain — usually mild-to-moderate and most pronounced during dose escalation, easing as the body adjusts. There are rarer but more serious considerations (e.g., pancreatitis, gallbladder issues, and boxed warnings around thyroid C-cell tumors seen in rodents), which is one reason it's a prescription-only, medically-supervised medication.
Semaglutide vs tirzepatide vs retatrutide
These represent three generations of incretin therapy. Semaglutide targets one pathway (GLP-1) and delivers ~15–21% weight loss depending on dose. Tirzepatide adds a second (GIP) for ~20–22.5%. Retatrutide adds a third (glucagon) and has shown even larger reductions in trials, though it's still investigational. More pathways has generally meant more weight loss — but also newer, less-established long-term data as you move down the list.
Important safety & legal note
Semaglutide is a prescription medication — it should only be used under the care of a licensed healthcare provider. The FDA has warned about unapproved and compounded GLP-1 products sold outside the regulated supply chain, citing dosing errors and quality concerns. Nothing here is a recommendation to obtain or use semaglutide outside a legitimate prescription.
✅ Clinically validated
- Among the best-evidenced drugs in modern medicine. FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and obesity (Wegovy) on the back of the SUSTAIN and STEP programmes — STEP 1 produced ~15% mean body-weight loss over 68 weeks against ~2.4% on placebo.
- SELECT then showed a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease but without diabetes. That is an outcome trial, not a surrogate marker, and it is the result that moved this from a weight drug to a cardiometabolic one.
📊 Correlative data
- Enormous real-world exposure, and what it added to the trials is the tail the trials were too short and too supervised to show: rapid weight regain on discontinuation, disproportionate lean-mass loss without resistance training and adequate protein, and gastroparesis reports that led to a label change.
- Compounded and grey-market semaglutide is a different product from a different supply chain. The trials do not transfer to a vial of uncertain provenance, and salt forms (semaglutide sodium/acetate) are not the studied molecule.
🧪 Theoretical / extrapolated
- A GLP-1 receptor agonist with a fatty-acid chain that binds albumin, giving a ~1-week half-life. It slows gastric emptying, suppresses appetite centrally and improves glucose-dependent insulin secretion.
- The mechanism predicts the side-effect profile precisely: nausea and early satiety are the gastric-emptying effect, not an intolerance, which is why titration works. It also predicts the muscle-loss problem — appetite suppression is indiscriminate about which tissue the deficit comes from.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Semaglutide — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centres. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognised signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumour signal exists in rodents and has not been demonstrated in humans; it is why the labelled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fibre and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Any time — but the same day each week
With a half-life measured in days you are dosing into a standing level, so the hour is irrelevant and the consistency is not. Pick a day and hold it; drifting the interval is what produces the peaks and troughs people mistake for the drug not working.
Food makes no meaningful difference at this half-life.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Semaglutide reconstitution calculator
Research reconstitution calculator
Where to get Semaglutide
Buy Semaglutide at Flawless Compounds →Semaglutide — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Semaglutide moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Semaglutide — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
Bloodwork to run alongside Semaglutide
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | The baseline you can't go back and get |
| Fasting Insulin | Falls as the drug works — useful proof it's doing something |
| Lipase | Pancreatitis is the rare serious adverse event to catch early |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake drops sharply |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Improves with weight loss, and worth documenting |
The On a GLP-1 (Semaglutide / Tirzepatide) panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 102 markers A–Z
Semaglutide — frequently asked questions
What is semaglutide?
Semaglutide is a once-weekly GLP-1 receptor agonist medication used for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Rybelsus is an oral form for diabetes.
How does semaglutide work for weight loss?
It mimics the gut hormone GLP-1 to reduce appetite, increase fullness, slow gastric emptying and improve blood-sugar control — which together lower calorie intake.
How much weight can you lose on semaglutide?
In the STEP 1 trial, semaglutide 2.4 mg produced about 14.9% average weight loss over 68 weeks (about 17.4% in those reaching the max dose). The 2026-approved 7.2 mg dose showed around 20.7% in its trial. Individual results vary.
How is semaglutide dosed?
In approved regimens it's titrated slowly, typically from about 0.25 mg weekly, stepping up roughly every 4 weeks toward a maintenance dose as tolerated — always set and supervised by a prescriber. Slow titration reduces nausea and dropouts.
What are the side effects of semaglutide?
Most commonly GI effects — nausea, vomiting, diarrhea, constipation — usually mild-to-moderate and worst during dose escalation. Rarer serious risks exist, which is why it's prescription-only and supervised.
Semaglutide vs tirzepatide — what's the difference?
Semaglutide targets one receptor (GLP-1); tirzepatide targets two (GLP-1 + GIP) and has produced larger average weight loss in trials. Which is appropriate is a medical decision.
Is compounded semaglutide safe?
The FDA has warned about unapproved and compounded GLP-1 products sold outside the regulated supply chain, citing dosing errors and quality concerns. Semaglutide should be used via a legitimate prescription under medical supervision.
References & further reading
- Semaglutide & tirzepatide clinical trials 2026 — what the research shows
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- STEP 1 trial extension — weight regain after withdrawal (PMC)
Want Coach Cam's exact Semaglutide protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Semaglutide is used for
Semaglutide appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.